Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097612 | 0.91 | HTT (0.38) | HTTHSD17B10SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23683255 | 0.83 | HTT (0.39) | HTTSMN1; SMN2FAP | |
| SCHEMBL22871647 | 0.82 | FAP (0.38) | HTTSMN1; SMN2FAPSIRT2SIRT1 | |
| SCHEMBL22238223 | 0.82 | LTA4H (0.41) | HTT | |
| SCHEMBL22841414 | 0.81 | LTA4H (0.37) | HTTSMN1; SMN2FAP | |
| SCHEMBL25564557 | 0.81 | FAP (0.38) | HTTSMN1; SMN2FAPSIRT2SIRT1 | |
| SCHEMBL21875528 | 0.81 | HSD17B10 (0.46) | HSD17B10 | |
| SCHEMBL20375584 | 0.81 | SIRT2 (0.37) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL20375515 | 0.81 | SIRT2 (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17706450 | 0.80 | SIRT2 (0.41) | FAPSIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | BICYCLETX LIMITED (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | BICYCLETX LIMITED (GB) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | NECTIN4, VCAM1, SIGLEC7 | HTT 1476/4885HSD17B10 3873/4885SMN1; SMN2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.